Form 4: Vaxcyte CEO Grant Pickering Trades Shares

Vaxcyte CEO Grant Pickering reported transactions involving company stock, including the acquisition of shares at $1.79 and the disposition of shares at $52.51, executed under a Rule 10b5-1 trading plan.

Summary

• Grant Pickering, CEO of Vaxcyte, Inc. (PCVX), reported a series of stock transactions on June 18, 2026.
• These transactions include the acquisition of 225 shares of common stock at a price of $1.79 per share.
• Additionally, 225 shares were disposed of at $52.51, 22,236 shares at $52.50, and 1,000 shares at $52.50.
• The dispositions were made pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026.
• Following these transactions, Pickering beneficially owns 497,164 shares directly.
• Some shares are held indirectly through trusts for his son and daughter.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative filing due to the significant stock sales by the CEO, despite being executed under a pre-arranged plan.

Positives

• The acquisition of 225 shares at a lower price ($1.79) could indicate a belief in future stock appreciation.
• The execution of trades under a Rule 10b5-1 plan suggests a pre-determined strategy for stock sales, which can be viewed positively for corporate governance and transparency.

Negatives

• The disposition of a significant number of shares (23,461 shares in total at $52.50/$52.51) by the CEO could be interpreted negatively by the market, potentially signaling a lack of confidence or a desire to diversify personal holdings.
• The sale price of $52.50/$52.51 is substantially higher than the acquisition price of $1.79, indicating a significant profit for the disposed shares.

Risks

• The primary risk is the market's perception of the CEO's stock sales, which could negatively impact the stock price.
• The reliance on a Rule 10b5-1 plan, while providing a defense against insider trading allegations, still involves the disposal of company stock by a key executive.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for Vaxcyte would depend on its business operations and market performance, not directly on this Form 4 filing.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
• Shares are held directly by a trust for the benefit of the Reporting Person's son.
• Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
• Option is fully vested and exercisable.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is often scrutinized by investors. While such plans are designed to provide liquidity and avoid accusations of insider trading, significant sales by a CEO can still lead to short-term price pressure as the market digests the information.

Corporate Governance

Stakeholder Impact

• Shareholders: May react negatively to the CEO's stock sales, potentially leading to short-term price declines. However, the Rule 10b5-1 plan provides a degree of reassurance.
• Employees: May experience uncertainty or concern if the stock price is negatively impacted by the CEO's sales.
• Management: The CEO's actions are under scrutiny, and future transactions will be closely watched.

Next Steps

• Continued monitoring of Vaxcyte's stock performance and any further insider transactions.
• Analysis of Vaxcyte's operational and financial results to understand the underlying business value.

Key Dates

Recommendation

The filing indicates significant stock sales by the CEO, which can be a bearish signal. However, these sales were conducted under a Rule 10b5-1 plan, suggesting a pre-determined strategy rather than a reaction to negative non-public information. Without further context on the company's performance or the reasons behind the plan, a 'hold' recommendation is prudent, balancing the insider selling with the structured nature of the trades.

Keywords

Vaxcyte, PCVX, Grant Pickering, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, CEO Transactions, Securities Exchange Act